Metraipolis › archive › dc_92ddcc35741e

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma — Europe PMC PMID:42358554

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42358554
DOI
10.3389/fonc.2026.1822419
License (as archived)
solo-consultazione
Archived
2026-10-31T14:55:08.679Z
SHA-256 of the archived text
1a0ef8f16a921e7c144e462cb3c292588553d48f0fb2f985559da938856732b0
Stable URL of this page
https://metraipolis.com/documento/dc_92ddcc35741e

How to cite

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma — Europe PMC PMID:42358554 — Europe PMC (en), https://europepmc.org/article/MED/42358554 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_92ddcc35741e (Metraipolis archive dc_92ddcc35741e, sha256 1a0ef8f16a921e7c144e462cb3c292588553d48f0fb2f985559da938856732b0)
BibTeX
@misc{dc92ddcc35741e,
  title = {Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma — Europe PMC PMID:42358554},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42358554},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_92ddcc35741e; sha256 1a0ef8f16a921e7c144e462cb3c292588553d48f0fb2f985559da938856732b0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42358554. Agents can read the archived copy with the MCP tool read_document.